2nd Quarter - Report
BIODESIX for BIODESIX
Firm
Client
Income
—
Expenses
$58,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
- Discussion draft to reform Section 101 of the Patent Act concerning patent eligibility
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Medicare/Medicaid MMM
-Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93) -payment of laboratory tests (S.1895; H.R. 3630) -Update packaging policy for protein-based tests (CY 2018 OPPS/ASC final rule)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Medical/Disease Research/Clinical Labs MED
-Regulation of laboratory developed tests (Verifying Accurate, Leading-edge IVCT Development (VALID) Act discussion draft)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.